GenMark Dx Says Platform Selected for Use in Warfarin Clinical Trial

GenMark said that its PCR-based eSensor warfarin sensitivity test panel and XT-8 platform have been selected for use in a clinical trial to assess the impact of genotype on the occurrence of adverse events during warfarin drug therapy.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.